Literature DB >> 24985952

Tubular calcium reabsorption and other aspects of calcium homeostasis in primary and secondary hyperparathyroidism.

Kenneth R Phelps, Kim S Stote, Darius Mason.   

Abstract

AIMS: Primary hyperparathyroidism (PHPT) causes hypercalcemia by increasing tubular calcium reabsorption. Because chronic kidney disease (CKD) is associated with normocalcemia, we inferred that calcium reabsorption is also normal, and hypothesized that normal reabsorption requires excessive parathyroid hormone (PTH) in CKD.
METHODS: The following were obtained in controls and patients with CKD or PHPT: estimated GFR (eGFR); concentrations of PTH 1-84, 1,25-dihydroxyvitamin D, and ultrafilterable and ionized calcium ([PTH], [1,25(OH)2D], [Ca]uf, [Ca]i); and ratios of calcium excreted or reabsorbed per volume of filtrate (ECa/Ccr, TRCa/Ccr). Pertinent linear regressions were examined.
RESULTS: In CKD, [PTH] was increased, but ECa/Ccr, TRCa/Ccr, [Ca]uf, and [Ca]i equaled control values. [PTH] was inversely related to eGFR but unrelated to [1,25(OH)2D]. TRCa/Ccr was constant at all [PTH]. In PHPT, [PTH] was no higher than in CKD, but TRCa/Ccr, [Ca]uf, and [Ca]i were increased. [1,25(OH)2D] correlated with [PTH]. In controls, TRCa/Ccr varied directly with [1,25(OH)2D] and inversely with [PTH].
CONCLUSIONS: In controls, calcium reabsorption rose with [1,25(OH)2D], and [PTH] fell in response. In PHPT, [PTH] determined [1,25(OH)2D]; together, the hormones increased calcium reabsorption and caused hypercalcemia. In CKD, normal calcium reabsorption required high [PTH].

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24985952     DOI: 10.5414/CN108223

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

1.  Race-specific associations of 25-hydroxyvitamin D and parathyroid hormone with cardiometabolic biomarkers among US white and black postmenopausal women.

Authors:  Jin Xia; Wanzhu Tu; JoAnn E Manson; Hongmei Nan; Aladdin H Shadyab; Jennifer W Bea; Ting-Yuan D Cheng; Lifang Hou; Yiqing Song
Journal:  Am J Clin Nutr       Date:  2020-08-01       Impact factor: 7.045

2.  Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.

Authors:  D Miyaoka; Y Imanishi; M Ohara; N Hayashi; Y Nagata; S Yamada; K Mori; M Emoto; M Inaba
Journal:  Osteoporos Int       Date:  2018-09-05       Impact factor: 4.507

3.  Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism.

Authors:  Kenneth R Phelps
Journal:  Nutrients       Date:  2017-04-26       Impact factor: 5.717

4.  The Source and Pathophysiologic Significance of Excreted Cadmium.

Authors:  Soisungwan Satarug; David A Vesey; Werawan Ruangyuttikarn; Muneko Nishijo; Glenda C Gobe; Kenneth R Phelps
Journal:  Toxics       Date:  2019-10-18

Review 5.  Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review.

Authors:  Maryam Zahedi; Reyhane Hizomi Arani; Maryam Rafati; Atieh Amouzegar; Farzad Hadaegh
Journal:  BMC Endocr Disord       Date:  2021-11-04       Impact factor: 2.763

6.  Ionized hypercalcemia in cats with azotemic chronic kidney disease (2012-2018).

Authors:  Dirk Hendrik Nicolaas van den Broek; Rebecca F Geddes; Nicola S Lötter; Yu-Mei Chang; Jonathan Elliott; Rosanne E Jepson
Journal:  J Vet Intern Med       Date:  2022-05-24       Impact factor: 3.175

7.  Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism.

Authors:  Kenneth R Phelps; Darren E Gemoets; Peter M May
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

8.  Chronic exposure to cadmium is associated with a marked reduction in glomerular filtration rate.

Authors:  Soisungwan Satarug; Kanyarat Boonprasert; Glenda C Gobe; Ronnatrai Ruenweerayut; David W Johnson; Kesara Na-Bangchang; David A Vesey
Journal:  Clin Kidney J       Date:  2018-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.